This company has been acquired
Resumen acción ETTX
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Competidores de Entasis Therapeutics Holdings Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.19 |
| 52 Week High | US$3.88 |
| 52 Week Low | US$1.40 |
| Beta | 1.33 |
| 1 Month Change | 0% |
| 3 Month Change | 18.38% |
| 1 Year Change | -14.79% |
| 3 Year Change | -65.77% |
| 5 Year Change | n/a |
| Change since IPO | -79.46% |
Noticias y actualizaciones recientes
Recent updates
Will Entasis Therapeutics Holdings (NASDAQ:ETTX) Spend Its Cash Wisely?
Dec 16
Entasis Therapeutics: AstraZeneca Spin-Out Developing Targeted Antibacterial Products
Nov 17Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?
Aug 19Entasis Therapeutics shares rise after lining up ETX0462 poster presentation
Jun 18What Kind Of Shareholders Own Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX)?
Feb 17
Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?
Dec 01Rentabilidad de los accionistas
| ETTX | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 0% | 0.1% | 0.9% |
| 1Y | -14.8% | 1.0% | 24.2% |
Rentabilidad frente al sector: ETTX exceeded the US Biotechs industry which returned -20.2% over the past year.
Rentabilidad vs. Mercado: ETTX exceeded the US Market which returned -17.2% over the past year.
Volatilidad de los precios
| ETTX volatility | |
|---|---|
| ETTX Average Weekly Movement | 6.6% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: ETTX has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: ETTX's weekly volatility (7%) has been stable over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2015 | 51 | Manos Perros | www.entasistx.com |
Resumen de fundamentos de Entasis Therapeutics Holdings Inc.
| Estadísticas fundamentales de ETTX | |
|---|---|
| Capitalización bursátil | US$104.80m |
| Beneficios(TTM) | -US$51.70m |
| Ingresos (TTM) | n/a |
0.0x
Ratio precio-ventas (PS)-2.0x
Ratio precio-beneficio (PE)¿Está ETTX sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ETTX | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$0 |
| Otros gastos | US$51.70m |
| Beneficios | -US$51.70m |
Últimos beneficios comunicados
Mar 31, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.08 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 90.2% |
¿Cómo se ha desempeñado ETTX a largo plazo?
Ver rendimiento histórico y comparativa